1. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.
- Author
-
Zhao, Yaqi, Laird, A, Roberts, Kathryn, Yafawi, Rolla, Kantarjian, Hagop, DeAngelo, Daniel, Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, OBrien, Susan, Jabbour, Elias, Cassaday, Ryan, Loyd, Melanie, Olsen, Scott, Neale, Geoffrey, Liu, Xueli, Vandendries, Erik, Advani, Anjali, and Mullighan, Charles
- Subjects
Humans ,Inotuzumab Ozogamicin ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Adult ,Female ,Male ,Middle Aged ,Treatment Outcome ,Aged ,Recurrence ,Antineoplastic Agents ,Immunological ,Young Adult ,Drug Resistance ,Neoplasm ,Adolescent - Abstract
The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterations and the efficacy of InO. Of 326 randomized patients, 91 (InO, n = 43; SC, n = 48) had samples evaluable for genomic analysis. The spectrum of gene fusions and other genomic alterations observed was comparable with prior studies of adult ALL. Responses to InO were observed in all leukemic subtypes, genomic alterations, and risk groups. Significantly higher rates of complete remission (CR)/CR with incomplete count recovery were observed with InO vs SC in patients with BCR::ABL1-like ALL (85.7% [6/7] vs 0% [0/5]; P = .0076), with TP53 alterations (100% [5/5] vs 12.5% [1/8]; P = .0047), and in the high-risk BCR::ABL1- (BCR::ABL1-like, low-hypodiploid, KMT2A-rearranged) group (83.3% [10/12] vs 10.5% [2/19]; P < .0001). This retrospective, exploratory analysis of the INO-VATE trial demonstrated potential for benefit with InO for patients with R/R ALL across leukemic subtypes, including BCR::ABL1-like ALL, and for those bearing diverse genomic alterations. Further confirmation of the efficacy of InO in patients with R/R ALL exhibiting the BCR::ABL1-like subtype or harboring TP53 alterations is warranted. This trial was registered at www.ClinicalTrials.gov as #NCT01564784.
- Published
- 2024